JI

JIN YANG PHARMACEUTICAL. CO., LTD

Develops and manufactures prescription drugs for cancer and metabolic disorders.

007370 | KO

Overview

Corporate Details

ISIN(s):
KR7007370000
LEI:
Country:
South Korea
Address:
서울특별시 서초구 효령로 231, 서울특별시

Description

JIN YANG PHARMACEUTICAL. CO., LTD. is a company engaged in the research, development, manufacturing, and sale of pharmaceutical products, with a primary focus on prescription drugs. The company operates a fully automated, high-tech manufacturing facility. Its research and development efforts are dedicated to creating advanced preventive and therapeutic treatments for various diseases. Key areas of R&D include the development of anticancer drugs through molecular biology research, particularly for leukemia, and therapies for metabolic disorders such as diabetes and obesity. The company also develops antivirals and explores formulations based on herbal preparations.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-12-24 00:00
현금ㆍ현물배당결정
Korean 9.4 KB
2025-12-16 00:00
주주명부폐쇄기간또는기준일설정
Korean 4.3 KB
2025-12-16 00:00
현금ㆍ현물배당을위한주주명부폐쇄(기준일)결정
Korean 5.8 KB
2025-09-17 00:00
주주총회소집공고
Korean 48.0 KB
2025-09-17 00:00
의결권대리행사권유참고서류
Korean 46.2 KB
2025-08-18 00:00
주주총회소집결의 (임시주주총회)
Korean 12.1 KB
2025-08-18 00:00
주주명부폐쇄기간또는기준일설정
Korean 4.4 KB
2025-08-13 00:00
반기보고서 (2025.06)
Korean 1.0 MB
2025-07-09 00:00
주식등의대량보유상황보고서(일반)
Korean 121.3 KB
2025-07-08 00:00
주요사항보고서(자기주식취득신탁계약해지결정)
Korean 31.3 KB
2025-07-08 00:00
주요사항보고서(자기주식취득신탁계약해지결정)
Korean 31.3 KB
2025-07-08 00:00
주요사항보고서(자기주식취득신탁계약해지결정)
Korean 31.3 KB
2025-07-08 00:00
신탁계약해지결과보고서
Korean 30.6 KB
2025-07-08 00:00
신탁계약해지결과보고서
Korean 25.2 KB
2025-07-08 00:00
신탁계약해지결과보고서
Korean 31.3 KB

Automate Your Workflow. Get a real-time feed of all JIN YANG PHARMACEUTICAL. CO., LTD filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for JIN YANG PHARMACEUTICAL. CO., LTD

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for JIN YANG PHARMACEUTICAL. CO., LTD via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Annexon, Inc. Logo
Clinical-stage biopharma developing complement medicines by inhibiting C1q.
United States of America
ANNX
ANTEROGEN CO., LTD. Logo
Develops and commercializes cell therapies and orphan drugs using adult stem cells.
South Korea
065660
Antibiotice S.A. Logo
Pharmaceutical firm manufacturing generic medicines, anti-infectives, and APIs.
Romania
ATB
Apellis Pharmaceuticals, Inc. Logo
Biopharmaceutical company developing therapies by targeting the complement cascade.
United States of America
APLS
Apimeds Pharmaceuticals US, Inc. Logo
Clinical-stage biopharma developing a bee venom drug and AI digital treasury solutions.
United States of America
APUS
Apogee Therapeutics, Inc. Logo
Clinical-stage biotech developing biologics for immunological and inflammatory diseases.
United States of America
APGE
Apollomics Inc. Logo
Clinical-stage biotech developing innovative oncology and combination therapies.
United States of America
APLM
Apontis Pharma AG Logo
Develops and markets fixed-dose combination drugs (Single Pills) for chronic diseases.
Germany
APPH
Applied Therapeutics, Inc. Logo
Clinical-stage biopharma developing novel drugs for rare metabolic and CNS diseases.
United States of America
APLT
Aprogen Biologics Inc. Logo
Develops and manufactures novel biologics and biosimilar antibody-based therapeutics.
South Korea
003060

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.